Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NextCure Inc
NXTC | US
1.34
USD-0.03
-2.19%
NXTC | US
About NextCure Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.34
Open
1.37
High
1.44
Low
1.34
NextCure Inc. a clinical-stage biopharmaceutical company engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410 an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762 a monoclonal antibody that binds specifically to B7-H4 a protein expressed on multiple tumor types; and NC525 a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure Inc. was incorporated in 2015 and is headquartered in Beltsville Maryland.
View LessNXTC | US
Risk
58.5
Sharpe
-0.04
Luna's Score
37/100
Recommendation
Sell
Luna says (NXTC | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
73.8%1 month
58.5%3 months
47.7%6 months
73.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.45
Debt to equity
0.07
Debt to assets
0.06
Ent. to EBITDA
0.51
Ent. to rev.
1.62
PEG
-
Other Fundamentals
EBITDA
-60.40M
MarketCap
37.49M
MarketCap(USD)
37.49M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-54.75
Short ratio
1.87
Short perc.
0.29
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.23
Range1M
0.23
Range3M
0.52
Volumes: Market Activity
Rel. volume
1.10
Price X volume
35.97K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.51 | - | Par |
| Ent. to Revenue | 1.62 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.45 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 47.66 | - | Lower Risk |
| Debt to Equity | 0.07 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 37.49M | - | Emerging |
